React Africa 2019: Universal Health Coverage Can Help Combat Antimicrobial Resistance 25/07/2019 Geoffrey Kamadi NAIROBI – Neonatal sepsis is one of the leading causes of newborn deaths globally, and increasing pathogen resistance to available first-line treatments is a prime example of rising antimicrobial resistance. That is why the Global Antibiotic Research and Development Partnership (GARDP) – a non-profit research organisation that develops new or improved antibiotic treatments – is […] Continue reading -> GARDP To Develop & Deliver 5 New Treatments For Antibiotic Resistant Infections By 2025 04/07/2019 David Branigan The Global Antibiotic Research & Development Partnership (GARDP) has announced its new “5 BY 25” strategy to mobilise global stakeholders to raise the €500 million needed to develop and deliver five new antibiotic treatments by 2025, to help tackle antimicrobial resistance (AMR). Drug-resistant infections already cause at least 700,000 deaths globally each year, and affect […] Continue reading -> WHO Launches Campaign to Combat Antimicrobial Resistance; Most Countries Fail to Report Aggregate Drug Use 18/06/2019 Elaine Ruth Fletcher The World Health Organization (WHO) today launched a global AWaRe campaign, which aims to support national health systems to make more judicious use of lifesaving drugs so as to combat a worldwide trend of antimicrobial resistance (AMR) – including increased pathogen resistance to common antibiotics, antivirals and anti-fungal medications. However, WHO’s own 2018 Report on […] Continue reading -> Major R&D Funding Needed To Reach 2030 Goal For Ending TB Epidemic 17/06/2019 Catherine Saez Nine months after a historic high-level UN meeting where countries pledged to end the global tuberculosis epidemic by 2030, a chronic lack of R&D financing jeopardises that ambitious goal, said expert panelists at a briefing on the TB R&D landscape last week in Geneva, hosted by South Africa’s Permanent Mission to the UN. While there […] Continue reading -> Expand Funding For Pandemic Preparedness: R&D Advocacy Group Says To US Congress 05/06/2019 David Branigan After applauding the United States Congress for passing a bill that aims to strengthen preparedness against global disease threats, an R&D advocacy group is now calling on Congressional leaders to ensure there is actually money allocated to fund an expanded set of activities. Image Credits: PATH/Eric Becker. Continue reading -> “No Time To Wait” – AMR Could Cause 10 Million Deaths Annually By 2050, Warns UN Report 29/04/2019 Elaine Ruth Fletcher Deaths from infections resistant to common antibiotics, antivirals and anti-parasitic drugs could increase more than ten-fold to 10 million deaths annually by 2050, warns a ground-breaking United Nations report released today. Image Credits: WHO/Quinn Mattingly, UN. Continue reading -> Lack of Access To Antibiotics Is A Major Global Health Challenge 11/04/2019 Editorial team [CDDEP Press Release] In a new report, CDDEP researchers identify key barriers that prevent access to antibiotics in LMICs and provides potential solutions to address them. Antibiotic resistance is an emerging global public health threat spurred by the overuse and misuse of antibiotics. While “overuse” of antibiotics is widely accepted as a major health challenge, […] Continue reading -> GARDP announces partnership with Calibr, HZI/HIPS and the University of Queensland in search for new antibiotics 11/04/2019 Editorial team [GARDP Press Release] [Geneva/San Francisco/Brisbane/Saarbrücken – 11 April 2019] Multi-actor partnership tests natural products and compound libraries for antibacterial activity Discovery efforts will focus on World Health Organization’s (WHO) priority pathogens The Global Antibiotic Research and Development Partnership (GARDP) is partnering with Calibr, the Helmholtz Centre for Infection Research (HZI), in particular its location Helmholtz-Institute […] Continue reading -> GARDP Set Up As Independent Legal Entity 02/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland – 2 April 2019 Continued close collaboration with founding partners will strengthen GARDP’s efforts to address AMR The Global Antibiotic Research and Development Partnership (GARDP) is now an independent legal entity following a successful three-year incubation, hosted by the Drugs for Neglected Diseases initiative (DNDi). During this time, GARDP has already begun […] Continue reading -> WHO Essential Medicines Review : Cancer Drugs, Insulin Analogues Draw Controversy 01/04/2019 Elaine Ruth Fletcher Expanding access to costly cancer treatments and the high price of new generation insulin formulas were among the controversial topics of debate today as the WHO Expert Committee on the Selection and Use of Essential Medicines convened for its biennial update of the list of over 400 drugs deemed most essential for treating public health needs […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
GARDP To Develop & Deliver 5 New Treatments For Antibiotic Resistant Infections By 2025 04/07/2019 David Branigan The Global Antibiotic Research & Development Partnership (GARDP) has announced its new “5 BY 25” strategy to mobilise global stakeholders to raise the €500 million needed to develop and deliver five new antibiotic treatments by 2025, to help tackle antimicrobial resistance (AMR). Drug-resistant infections already cause at least 700,000 deaths globally each year, and affect […] Continue reading -> WHO Launches Campaign to Combat Antimicrobial Resistance; Most Countries Fail to Report Aggregate Drug Use 18/06/2019 Elaine Ruth Fletcher The World Health Organization (WHO) today launched a global AWaRe campaign, which aims to support national health systems to make more judicious use of lifesaving drugs so as to combat a worldwide trend of antimicrobial resistance (AMR) – including increased pathogen resistance to common antibiotics, antivirals and anti-fungal medications. However, WHO’s own 2018 Report on […] Continue reading -> Major R&D Funding Needed To Reach 2030 Goal For Ending TB Epidemic 17/06/2019 Catherine Saez Nine months after a historic high-level UN meeting where countries pledged to end the global tuberculosis epidemic by 2030, a chronic lack of R&D financing jeopardises that ambitious goal, said expert panelists at a briefing on the TB R&D landscape last week in Geneva, hosted by South Africa’s Permanent Mission to the UN. While there […] Continue reading -> Expand Funding For Pandemic Preparedness: R&D Advocacy Group Says To US Congress 05/06/2019 David Branigan After applauding the United States Congress for passing a bill that aims to strengthen preparedness against global disease threats, an R&D advocacy group is now calling on Congressional leaders to ensure there is actually money allocated to fund an expanded set of activities. Image Credits: PATH/Eric Becker. Continue reading -> “No Time To Wait” – AMR Could Cause 10 Million Deaths Annually By 2050, Warns UN Report 29/04/2019 Elaine Ruth Fletcher Deaths from infections resistant to common antibiotics, antivirals and anti-parasitic drugs could increase more than ten-fold to 10 million deaths annually by 2050, warns a ground-breaking United Nations report released today. Image Credits: WHO/Quinn Mattingly, UN. Continue reading -> Lack of Access To Antibiotics Is A Major Global Health Challenge 11/04/2019 Editorial team [CDDEP Press Release] In a new report, CDDEP researchers identify key barriers that prevent access to antibiotics in LMICs and provides potential solutions to address them. Antibiotic resistance is an emerging global public health threat spurred by the overuse and misuse of antibiotics. While “overuse” of antibiotics is widely accepted as a major health challenge, […] Continue reading -> GARDP announces partnership with Calibr, HZI/HIPS and the University of Queensland in search for new antibiotics 11/04/2019 Editorial team [GARDP Press Release] [Geneva/San Francisco/Brisbane/Saarbrücken – 11 April 2019] Multi-actor partnership tests natural products and compound libraries for antibacterial activity Discovery efforts will focus on World Health Organization’s (WHO) priority pathogens The Global Antibiotic Research and Development Partnership (GARDP) is partnering with Calibr, the Helmholtz Centre for Infection Research (HZI), in particular its location Helmholtz-Institute […] Continue reading -> GARDP Set Up As Independent Legal Entity 02/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland – 2 April 2019 Continued close collaboration with founding partners will strengthen GARDP’s efforts to address AMR The Global Antibiotic Research and Development Partnership (GARDP) is now an independent legal entity following a successful three-year incubation, hosted by the Drugs for Neglected Diseases initiative (DNDi). During this time, GARDP has already begun […] Continue reading -> WHO Essential Medicines Review : Cancer Drugs, Insulin Analogues Draw Controversy 01/04/2019 Elaine Ruth Fletcher Expanding access to costly cancer treatments and the high price of new generation insulin formulas were among the controversial topics of debate today as the WHO Expert Committee on the Selection and Use of Essential Medicines convened for its biennial update of the list of over 400 drugs deemed most essential for treating public health needs […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
WHO Launches Campaign to Combat Antimicrobial Resistance; Most Countries Fail to Report Aggregate Drug Use 18/06/2019 Elaine Ruth Fletcher The World Health Organization (WHO) today launched a global AWaRe campaign, which aims to support national health systems to make more judicious use of lifesaving drugs so as to combat a worldwide trend of antimicrobial resistance (AMR) – including increased pathogen resistance to common antibiotics, antivirals and anti-fungal medications. However, WHO’s own 2018 Report on […] Continue reading -> Major R&D Funding Needed To Reach 2030 Goal For Ending TB Epidemic 17/06/2019 Catherine Saez Nine months after a historic high-level UN meeting where countries pledged to end the global tuberculosis epidemic by 2030, a chronic lack of R&D financing jeopardises that ambitious goal, said expert panelists at a briefing on the TB R&D landscape last week in Geneva, hosted by South Africa’s Permanent Mission to the UN. While there […] Continue reading -> Expand Funding For Pandemic Preparedness: R&D Advocacy Group Says To US Congress 05/06/2019 David Branigan After applauding the United States Congress for passing a bill that aims to strengthen preparedness against global disease threats, an R&D advocacy group is now calling on Congressional leaders to ensure there is actually money allocated to fund an expanded set of activities. Image Credits: PATH/Eric Becker. Continue reading -> “No Time To Wait” – AMR Could Cause 10 Million Deaths Annually By 2050, Warns UN Report 29/04/2019 Elaine Ruth Fletcher Deaths from infections resistant to common antibiotics, antivirals and anti-parasitic drugs could increase more than ten-fold to 10 million deaths annually by 2050, warns a ground-breaking United Nations report released today. Image Credits: WHO/Quinn Mattingly, UN. Continue reading -> Lack of Access To Antibiotics Is A Major Global Health Challenge 11/04/2019 Editorial team [CDDEP Press Release] In a new report, CDDEP researchers identify key barriers that prevent access to antibiotics in LMICs and provides potential solutions to address them. Antibiotic resistance is an emerging global public health threat spurred by the overuse and misuse of antibiotics. While “overuse” of antibiotics is widely accepted as a major health challenge, […] Continue reading -> GARDP announces partnership with Calibr, HZI/HIPS and the University of Queensland in search for new antibiotics 11/04/2019 Editorial team [GARDP Press Release] [Geneva/San Francisco/Brisbane/Saarbrücken – 11 April 2019] Multi-actor partnership tests natural products and compound libraries for antibacterial activity Discovery efforts will focus on World Health Organization’s (WHO) priority pathogens The Global Antibiotic Research and Development Partnership (GARDP) is partnering with Calibr, the Helmholtz Centre for Infection Research (HZI), in particular its location Helmholtz-Institute […] Continue reading -> GARDP Set Up As Independent Legal Entity 02/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland – 2 April 2019 Continued close collaboration with founding partners will strengthen GARDP’s efforts to address AMR The Global Antibiotic Research and Development Partnership (GARDP) is now an independent legal entity following a successful three-year incubation, hosted by the Drugs for Neglected Diseases initiative (DNDi). During this time, GARDP has already begun […] Continue reading -> WHO Essential Medicines Review : Cancer Drugs, Insulin Analogues Draw Controversy 01/04/2019 Elaine Ruth Fletcher Expanding access to costly cancer treatments and the high price of new generation insulin formulas were among the controversial topics of debate today as the WHO Expert Committee on the Selection and Use of Essential Medicines convened for its biennial update of the list of over 400 drugs deemed most essential for treating public health needs […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Major R&D Funding Needed To Reach 2030 Goal For Ending TB Epidemic 17/06/2019 Catherine Saez Nine months after a historic high-level UN meeting where countries pledged to end the global tuberculosis epidemic by 2030, a chronic lack of R&D financing jeopardises that ambitious goal, said expert panelists at a briefing on the TB R&D landscape last week in Geneva, hosted by South Africa’s Permanent Mission to the UN. While there […] Continue reading -> Expand Funding For Pandemic Preparedness: R&D Advocacy Group Says To US Congress 05/06/2019 David Branigan After applauding the United States Congress for passing a bill that aims to strengthen preparedness against global disease threats, an R&D advocacy group is now calling on Congressional leaders to ensure there is actually money allocated to fund an expanded set of activities. Image Credits: PATH/Eric Becker. Continue reading -> “No Time To Wait” – AMR Could Cause 10 Million Deaths Annually By 2050, Warns UN Report 29/04/2019 Elaine Ruth Fletcher Deaths from infections resistant to common antibiotics, antivirals and anti-parasitic drugs could increase more than ten-fold to 10 million deaths annually by 2050, warns a ground-breaking United Nations report released today. Image Credits: WHO/Quinn Mattingly, UN. Continue reading -> Lack of Access To Antibiotics Is A Major Global Health Challenge 11/04/2019 Editorial team [CDDEP Press Release] In a new report, CDDEP researchers identify key barriers that prevent access to antibiotics in LMICs and provides potential solutions to address them. Antibiotic resistance is an emerging global public health threat spurred by the overuse and misuse of antibiotics. While “overuse” of antibiotics is widely accepted as a major health challenge, […] Continue reading -> GARDP announces partnership with Calibr, HZI/HIPS and the University of Queensland in search for new antibiotics 11/04/2019 Editorial team [GARDP Press Release] [Geneva/San Francisco/Brisbane/Saarbrücken – 11 April 2019] Multi-actor partnership tests natural products and compound libraries for antibacterial activity Discovery efforts will focus on World Health Organization’s (WHO) priority pathogens The Global Antibiotic Research and Development Partnership (GARDP) is partnering with Calibr, the Helmholtz Centre for Infection Research (HZI), in particular its location Helmholtz-Institute […] Continue reading -> GARDP Set Up As Independent Legal Entity 02/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland – 2 April 2019 Continued close collaboration with founding partners will strengthen GARDP’s efforts to address AMR The Global Antibiotic Research and Development Partnership (GARDP) is now an independent legal entity following a successful three-year incubation, hosted by the Drugs for Neglected Diseases initiative (DNDi). During this time, GARDP has already begun […] Continue reading -> WHO Essential Medicines Review : Cancer Drugs, Insulin Analogues Draw Controversy 01/04/2019 Elaine Ruth Fletcher Expanding access to costly cancer treatments and the high price of new generation insulin formulas were among the controversial topics of debate today as the WHO Expert Committee on the Selection and Use of Essential Medicines convened for its biennial update of the list of over 400 drugs deemed most essential for treating public health needs […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Expand Funding For Pandemic Preparedness: R&D Advocacy Group Says To US Congress 05/06/2019 David Branigan After applauding the United States Congress for passing a bill that aims to strengthen preparedness against global disease threats, an R&D advocacy group is now calling on Congressional leaders to ensure there is actually money allocated to fund an expanded set of activities. Image Credits: PATH/Eric Becker. Continue reading -> “No Time To Wait” – AMR Could Cause 10 Million Deaths Annually By 2050, Warns UN Report 29/04/2019 Elaine Ruth Fletcher Deaths from infections resistant to common antibiotics, antivirals and anti-parasitic drugs could increase more than ten-fold to 10 million deaths annually by 2050, warns a ground-breaking United Nations report released today. Image Credits: WHO/Quinn Mattingly, UN. Continue reading -> Lack of Access To Antibiotics Is A Major Global Health Challenge 11/04/2019 Editorial team [CDDEP Press Release] In a new report, CDDEP researchers identify key barriers that prevent access to antibiotics in LMICs and provides potential solutions to address them. Antibiotic resistance is an emerging global public health threat spurred by the overuse and misuse of antibiotics. While “overuse” of antibiotics is widely accepted as a major health challenge, […] Continue reading -> GARDP announces partnership with Calibr, HZI/HIPS and the University of Queensland in search for new antibiotics 11/04/2019 Editorial team [GARDP Press Release] [Geneva/San Francisco/Brisbane/Saarbrücken – 11 April 2019] Multi-actor partnership tests natural products and compound libraries for antibacterial activity Discovery efforts will focus on World Health Organization’s (WHO) priority pathogens The Global Antibiotic Research and Development Partnership (GARDP) is partnering with Calibr, the Helmholtz Centre for Infection Research (HZI), in particular its location Helmholtz-Institute […] Continue reading -> GARDP Set Up As Independent Legal Entity 02/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland – 2 April 2019 Continued close collaboration with founding partners will strengthen GARDP’s efforts to address AMR The Global Antibiotic Research and Development Partnership (GARDP) is now an independent legal entity following a successful three-year incubation, hosted by the Drugs for Neglected Diseases initiative (DNDi). During this time, GARDP has already begun […] Continue reading -> WHO Essential Medicines Review : Cancer Drugs, Insulin Analogues Draw Controversy 01/04/2019 Elaine Ruth Fletcher Expanding access to costly cancer treatments and the high price of new generation insulin formulas were among the controversial topics of debate today as the WHO Expert Committee on the Selection and Use of Essential Medicines convened for its biennial update of the list of over 400 drugs deemed most essential for treating public health needs […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
“No Time To Wait” – AMR Could Cause 10 Million Deaths Annually By 2050, Warns UN Report 29/04/2019 Elaine Ruth Fletcher Deaths from infections resistant to common antibiotics, antivirals and anti-parasitic drugs could increase more than ten-fold to 10 million deaths annually by 2050, warns a ground-breaking United Nations report released today. Image Credits: WHO/Quinn Mattingly, UN. Continue reading -> Lack of Access To Antibiotics Is A Major Global Health Challenge 11/04/2019 Editorial team [CDDEP Press Release] In a new report, CDDEP researchers identify key barriers that prevent access to antibiotics in LMICs and provides potential solutions to address them. Antibiotic resistance is an emerging global public health threat spurred by the overuse and misuse of antibiotics. While “overuse” of antibiotics is widely accepted as a major health challenge, […] Continue reading -> GARDP announces partnership with Calibr, HZI/HIPS and the University of Queensland in search for new antibiotics 11/04/2019 Editorial team [GARDP Press Release] [Geneva/San Francisco/Brisbane/Saarbrücken – 11 April 2019] Multi-actor partnership tests natural products and compound libraries for antibacterial activity Discovery efforts will focus on World Health Organization’s (WHO) priority pathogens The Global Antibiotic Research and Development Partnership (GARDP) is partnering with Calibr, the Helmholtz Centre for Infection Research (HZI), in particular its location Helmholtz-Institute […] Continue reading -> GARDP Set Up As Independent Legal Entity 02/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland – 2 April 2019 Continued close collaboration with founding partners will strengthen GARDP’s efforts to address AMR The Global Antibiotic Research and Development Partnership (GARDP) is now an independent legal entity following a successful three-year incubation, hosted by the Drugs for Neglected Diseases initiative (DNDi). During this time, GARDP has already begun […] Continue reading -> WHO Essential Medicines Review : Cancer Drugs, Insulin Analogues Draw Controversy 01/04/2019 Elaine Ruth Fletcher Expanding access to costly cancer treatments and the high price of new generation insulin formulas were among the controversial topics of debate today as the WHO Expert Committee on the Selection and Use of Essential Medicines convened for its biennial update of the list of over 400 drugs deemed most essential for treating public health needs […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Lack of Access To Antibiotics Is A Major Global Health Challenge 11/04/2019 Editorial team [CDDEP Press Release] In a new report, CDDEP researchers identify key barriers that prevent access to antibiotics in LMICs and provides potential solutions to address them. Antibiotic resistance is an emerging global public health threat spurred by the overuse and misuse of antibiotics. While “overuse” of antibiotics is widely accepted as a major health challenge, […] Continue reading -> GARDP announces partnership with Calibr, HZI/HIPS and the University of Queensland in search for new antibiotics 11/04/2019 Editorial team [GARDP Press Release] [Geneva/San Francisco/Brisbane/Saarbrücken – 11 April 2019] Multi-actor partnership tests natural products and compound libraries for antibacterial activity Discovery efforts will focus on World Health Organization’s (WHO) priority pathogens The Global Antibiotic Research and Development Partnership (GARDP) is partnering with Calibr, the Helmholtz Centre for Infection Research (HZI), in particular its location Helmholtz-Institute […] Continue reading -> GARDP Set Up As Independent Legal Entity 02/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland – 2 April 2019 Continued close collaboration with founding partners will strengthen GARDP’s efforts to address AMR The Global Antibiotic Research and Development Partnership (GARDP) is now an independent legal entity following a successful three-year incubation, hosted by the Drugs for Neglected Diseases initiative (DNDi). During this time, GARDP has already begun […] Continue reading -> WHO Essential Medicines Review : Cancer Drugs, Insulin Analogues Draw Controversy 01/04/2019 Elaine Ruth Fletcher Expanding access to costly cancer treatments and the high price of new generation insulin formulas were among the controversial topics of debate today as the WHO Expert Committee on the Selection and Use of Essential Medicines convened for its biennial update of the list of over 400 drugs deemed most essential for treating public health needs […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
GARDP announces partnership with Calibr, HZI/HIPS and the University of Queensland in search for new antibiotics 11/04/2019 Editorial team [GARDP Press Release] [Geneva/San Francisco/Brisbane/Saarbrücken – 11 April 2019] Multi-actor partnership tests natural products and compound libraries for antibacterial activity Discovery efforts will focus on World Health Organization’s (WHO) priority pathogens The Global Antibiotic Research and Development Partnership (GARDP) is partnering with Calibr, the Helmholtz Centre for Infection Research (HZI), in particular its location Helmholtz-Institute […] Continue reading -> GARDP Set Up As Independent Legal Entity 02/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland – 2 April 2019 Continued close collaboration with founding partners will strengthen GARDP’s efforts to address AMR The Global Antibiotic Research and Development Partnership (GARDP) is now an independent legal entity following a successful three-year incubation, hosted by the Drugs for Neglected Diseases initiative (DNDi). During this time, GARDP has already begun […] Continue reading -> WHO Essential Medicines Review : Cancer Drugs, Insulin Analogues Draw Controversy 01/04/2019 Elaine Ruth Fletcher Expanding access to costly cancer treatments and the high price of new generation insulin formulas were among the controversial topics of debate today as the WHO Expert Committee on the Selection and Use of Essential Medicines convened for its biennial update of the list of over 400 drugs deemed most essential for treating public health needs […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
GARDP Set Up As Independent Legal Entity 02/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland – 2 April 2019 Continued close collaboration with founding partners will strengthen GARDP’s efforts to address AMR The Global Antibiotic Research and Development Partnership (GARDP) is now an independent legal entity following a successful three-year incubation, hosted by the Drugs for Neglected Diseases initiative (DNDi). During this time, GARDP has already begun […] Continue reading -> WHO Essential Medicines Review : Cancer Drugs, Insulin Analogues Draw Controversy 01/04/2019 Elaine Ruth Fletcher Expanding access to costly cancer treatments and the high price of new generation insulin formulas were among the controversial topics of debate today as the WHO Expert Committee on the Selection and Use of Essential Medicines convened for its biennial update of the list of over 400 drugs deemed most essential for treating public health needs […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WHO Essential Medicines Review : Cancer Drugs, Insulin Analogues Draw Controversy 01/04/2019 Elaine Ruth Fletcher Expanding access to costly cancer treatments and the high price of new generation insulin formulas were among the controversial topics of debate today as the WHO Expert Committee on the Selection and Use of Essential Medicines convened for its biennial update of the list of over 400 drugs deemed most essential for treating public health needs […] Continue reading -> Posts navigation Older postsNewer posts